The objective of the study is to evaluate the safety and efficacy of DMT210 Gel, 5% compared to vehicle control following 28 days of twice-daily topical application to selected target lesions in male and female patients with mild to moderate atopic dermatitis (AD).

Inclusion Criteria:

• Male or female 12 years or older
• Patient has chronic, stable AD that has been present for at least 3 months with 5-35% (inclusive) BSA (Body Surface Area) of AD involvement
• Patient has two analogous, Target Lesions; one lesion within each of the two Treatment Areas
• Patient is willing and able to comply with the protocol

Exclusion Criteria:

• Patient has used topical therapies for AD within the Treatment Areas 2 weeks before baseline